A. Curran

发表

A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics

Dave Singh, G. Layton, N. Khan, 2019, British journal of clinical pharmacology.

Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats.

J. Phillips, J. Hunter, R. Chapman, 2011, Pulmonary pharmacology & therapeutics.

CXCR2 antagonists for the treatment of pulmonary disease.

J. Phillips, D. Lundell, D. Lundell, 2009, Pharmacology & therapeutics.

Allergic Diseases Caused by Aspergillus Species in Patients with Cystic Fibrosis

D. Hava, A. Curran, 2021, Antibiotics.

A New Natural Defense Against Airborne Pathogens

R. Langer, A. Hickey, W. Dehaan, 2020, QRB Discovery.

Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug

Fadi Xu, M. Corboz, Zhili Li, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Changes in Upper and Lower Airway Inflammation Following Administration of Mometasone Furoate in Allergen-Challenged Brown Norway Rats

J. Phillips, R. Mcleod, R. Chapman, 2008, Arzneimittelforschung.

CXCR2 antagonists for the treatment of pulmonary disease.

J. Phillips, D. Lundell, J. Fine, 2009, Pharmacology & therapeutics.

Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data

K. Kane, A. Curran, Ian E. Templeton, 2023, The AAPS Journal.